CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionReturn on equity is -111.4%, lower than 95% of its Medical Devices peers (median 3%)
- FinancialsAltman Z-Score -2.15: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
548.23MUSDvs all stocks (USD)
Revenue (TTM)
99.53MUSDvs all stocks (USD)
Profit Margin
-21.67%vs Medical Devices peers
Beta
1.89xvs all stocks
52-Week Change
71.79%vs all stocks
Market Capitalization
548.23MUSDvs all stocks (USD)
Enterprise Value
578.00MUSDvs all stocks (USD)
Forward P/E
-55.41xvs Medical Devices peers
Price to Sales (TTM)
5.64xvs Medical Devices peers
Price to Book (MRQ)
38.66xvs Medical Devices peers
Enterprise to Revenue
5.81xvs Medical Devices peers
Enterprise to EBITDA
-35.01xvs Medical Devices peers
Gross Margin
81.78%vs Medical Devices peers
Profit Margin
-21.67%vs Medical Devices peers
Operating Margin
-25.23%vs Medical Devices peers
Return on Assets (TTM)
-10.02%vs Medical Devices peers
Return on Equity (TTM)
-111.38%vs Medical Devices peers
Revenue (TTM)
99.53MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.99USDUpdated Jul 19, 2026Quarterly Revenue Growth
-2.00%vs Medical Devices peers
Gross Profit (TTM)
77.93MUSDvs all stocks (USD)
EBITDA (TTM)
-16.51MUSDvs all stocks (USD)
Net Income (TTM)
-21.57MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-2.02%vs Medical Devices peers
Operating Cash Flow (TTM)
-9.42MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.74MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
99.99MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
22.77MUSDFY2025 · Dec 31, 2025Gross Profit
77.22MUSDFY2025 · Dec 31, 2025Operating Income
-16.34MUSDvs all stocks (USD)
Pre-tax Income
-21.46MUSDFY2025 · Dec 31, 2025Net Income
-21.46MUSDFY2025 · Dec 31, 2025EBIT
-14.01MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-12.06MUSDFY2025 · Dec 31, 2025Research & Development
27.89MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
65.67MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.82MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.46MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-21.46MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-16.16MUSDFY2025 · Dec 31, 2025Free Cash Flow
-16.49MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
21.81MUSDFY2025 · Dec 31, 2025Interest Paid
6.20MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-21.46MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.95MUSDFY2025 · Dec 31, 2025Stock-based Compensation
11.09MUSDFY2025 · Dec 31, 2025Other Non-cash Items
775.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.83MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-730.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.95MUSDFY2025 · Dec 31, 2025Capital Expenditures
-332.00KUSDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-332.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
58.44MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-60.51MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-49.55MUSDFY2025 · Dec 31, 2025Other Financing Charges
-543.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
17.73MUSDFY2025 · Dec 31, 2025Shares Outstanding
33.91MSharesUpdated Jul 19, 2026Float Shares
23.29MSharesUpdated Jul 19, 2026Shares Short
898.59KSharesUpdated Jul 19, 2026Short Ratio
4.93daysvs all stocks
Short % of Shares Outstanding
3.04%vs all stocks
% Held by Insiders
4.04%vs all stocks
% Held by Institutions
96.28%vs all stocks
Total Cash (MRQ)
53.98MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.58USDUpdated Jul 19, 2026Total Debt (MRQ)
70.46MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
4.87xvs Medical Devices peers
Current Ratio (MRQ)
5.38xvs Medical Devices peers
Book Value per Share (MRQ)
0.4260USDUpdated Jul 19, 2026Total Assets
105.56MUSDvs all stocks (USD)
Total Current Assets
94.07MUSDFY2025 · Dec 31, 2025Total Liabilities
86.53MUSDFY2025 · Dec 31, 2025Total Non-current Assets
11.49MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
68.72MUSDFY2025 · Dec 31, 2025Total Current Liabilities
17.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
21.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
39.37MUSDFY2025 · Dec 31, 2025Accounts Receivable
14.68MUSDFY2025 · Dec 31, 2025Inventory
16.90MUSDFY2025 · Dec 31, 2025Accounts Payable
2.22MUSDFY2025 · Dec 31, 2025Short-term Debt
2.12MUSDFY2025 · Dec 31, 2025Deferred Revenue
141.00KUSDFY2025 · Dec 31, 2025Long-term Debt
68.72MUSDFY2025 · Dec 31, 2025Common Stock (Book)
34.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-552.41MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
19.03MUSDvs all stocks (USD)
52-Week Low
7.56USDUpdated Jul 19, 202652-Week High
19.60USDUpdated Jul 19, 202652-Week Change
71.79%vs all stocks
Beta
1.89xvs all stocks
50-Day MA
16.34USDUpdated Jul 19, 2026200-Day MA
14.86USDUpdated Jul 19, 2026Avg 10-Day Volume
142.66KSharesUpdated Jul 19, 2026Avg 30-Day Volume
169.06KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.6500USDUpdated Jul 19, 2026Other Income / Expense
-486.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -111.4%, lower than 95% of its Medical Devices peers (median 3%)Significant
Return on equity: -1.11Industry median: 0.03Industry P5: -0.69Peers compared: 102
Debt-to-equity is 4.87×, higher than 95% of its Medical Devices peers (median 0.11×)Significant
Debt-to-equity: 4.87Industry median: 0.11Industry P95: 1.20Peers compared: 102
Price-to-book is 38.66×, higher than 95% of its Medical Devices peers (median 2.69×)Significant
Price-to-book: 38.66Industry median: 2.69Industry P95: 16.17Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.82Profit Margin: -0.22
Significant cash reserves alongside high leverageNotable
Cash (USD): 53,981,000Total Debt (USD): 70,462,000Debt-to-Equity: 4.87
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 5.38Altman Z-Score: -2.15
Prioritizing buybacks over growth reinvestmentNotable
Buyback Intensity: 0.09Revenue Growth YoY: -0.02
Financial Health
Altman Z-Score -2.15: distress zoneCritical
Altman Z-Score: -2.15
Low earnings qualitySignificant
Earnings Quality Score: -0.63
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Sailun Biotech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Relmada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pulike Biological Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Well Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Altimmune, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TaiMed Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow